Press Releases Archives - Page 3 of 3

February 12, 2022

TAE Life Sciences Partners with BEC to Incorporate Specialized Robotic Patient Positioning System in its Alphabeam™ System for High-Precision Boron Neutron Capture Therapy

9/2021 | Business Wire

During BNCT, it is essential that the patient is positioned accurately in relation to the radiation beam and that the radiation therapist has the ability to adjust the patient’s position throughout the whole treatment session. BEC will be developing a unique chair setup that will allow for flexible patient treatment in a seated position in addition to the traditional treatment couch configuration. Exclusively designed for TLS’ Alphabeam™ Neutron System, the chair is optimal for treating specific types of head and neck cancers.

February 12, 2022

TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China

9/2021 | Business Wire

TLS’ Neutron Beam System enables a new treatment modality for patients diagnosed with the most aggressive and recurrent cancers such as gliomas, head and neck tumors, and melanomas, by delivering more precise, targeted radiation to cancer cells while sparing damage to surrounding healthy tissue. This technique holds promise in treating patients with cancer for whom other treatment options have been exhausted or are unavailable.

February 12, 2022

TAE Life Sciences Identifies Proprietary Drug Candidates to Support Boron Neutron Capture Therapy (BNCT)

2021 | Business Wire

“TLS is the only company developing comprehensive, in-house target drugs as well as a neutron technology system called Alphabeam™ to enable the next-generation in biologically targeted radiation therapy. Today’s news brings us closer to our goal of providing new hope to patients with the most difficult to treat cancers,” said Bruce Bauer, PhD, CEO of TAE Life Sciences. “Historically, brain, head and neck, and melanoma cancers have been treated with BNCT and studies have shown improvements in survival compared to other cancer therapies. New boron drugs expand the potential to treat other indications including breast, lung and liver cancers.”

October 27, 2020

TAE Life Sciences and CNAO (National Center of Oncological Hadrontherapy) Announce a Research and Clinical Collaboration for the Implementation of a New Facility with Boron Neutron Capture Therapy System in Italy

2020 | Business Wire

TAE Life Sciences (TLS), a biologically-targeted radiation therapy company developing a breakthrough, accelerator-based boron neutron capture therapy (BNCT) system, today announced that it has entered into an agreement with National Center of Oncological Hadrontherapy (CNAO) to provide its Alphabeam™ Neutron System for the treatment of invasive, recurrent and difficult to treat cancers.

August 7, 2020

TAE Life Sciences to Present at Solebury Trout Summer 2020 Private Company Showcase

2020 | Business Wire

TAE Life Sciences (TLS) is a privately-held biotechnology company committed to developing a new biologically-targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TLS is developing the next generation targeted boron drugs and low-energy accelerator-based neutron source – optimized for an in-hospital BNCT program that can one day treat patients with the most aggressive and recurrent cancers.

June 2, 2020

TAE Life Sciences Secures $30M in Initial B Round Phase to Accelerate Development of Unique Boron Delivery Drugs for Novel Cancer Treatment

2020 | Market Watch

TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), announced the launch of an innovative in-house boron delivery drug development program supported by an influx of $30M in funding. The initial phase of the B-round funds comes from a consortium of investors including ARTIS Ventures, who led the company's initial funding in 2018.

September 15, 2019

TAE Life Sciences Announces Scientific Advisory Board to Advance Cancer Research in Boron-Neutron Capture Therapy

2019 | Cision PR Newswire | Read Now

BNCT is unique in its ability to deliver targeted therapy to destroy cancer cells with biological precision and has shown compelling results in treating some of the most challenging cancers, including brain, head and neck tumors and melanomas. BNCT uses the benign boron-10 isotope in a targeting drug that naturally embeds within fast-growing cancer cells, which then receive an intense, highly localized dose of radiation activated by a low-energy neutron beam.

May 17, 2019

Boron Neutron Capture Therapy Progresses Towards Clinical Cancer Treatments

2019 | Physics World | Read Now

The main obstacle to BNCT has been that a nuclear reactor was required to generate the neutron beams needed for treatments. To overcome this problem, TAE Life Sciences is developing an accelerator-based neutron source. “We have created a low-energy neutron beam source that is reliable, compact and can be installed in a hospital facility,” says Bruce Bauer, CEO of TAE Life Sciences. “This changes the game on BNCT.”

January 7, 2019

TAE Life Sciences Adds Seasoned Chief Operating Officer to Scale New Radiation Treatment Platform

Robert Hill brings expertise in the technical and clinical development of radiation systems to speed platform research and commercialization.

FOOTHILL RANCH, CA, January 7, 2019 – TAE Life Sciences, an oncology company pioneering a new treatment platform focused on addressing limitations in current cancer therapy, is pleased to announce the appointment of Robert Hill as Chief Operating Officer. With expertise in technology development and clinical adoption in the field of Radiation Oncology, and a wealth of experience in commercializing medical technology, Hill’s appointment furthers TAE Life Sciences’ ability to scale its efforts to bring a compelling new technology for treating cancer patients around the world.

“Rob’s strength in the innovation and commercialization of medical technology will be a great advantage as we develop the market for our innovative approach to cancer treatment,” said Bruce Bauer, CEO of TAE Life Sciences. “We are excited about the knowledge and energy he brings to our team.”

As Chief Operating Officer of TAE Life Sciences, Hill will use his extensive knowledge in the development of radiation oncology systems to amplify and accelerate the commercialization of a full clinical system for TAE Life Sciences’ proprietary solution for Boron Neutron Capture Therapy (BNCT).

TAE Life Sciences is leveraging unique accelerator-based neutron beam technology developed by TAE Technologies, Inc., the world's largest and most advanced private fusion energy company. TAE Life Sciences has exclusively licensed intellectual property from the fusion energy leader to bring promising treatment potential for head and neck, glioblastoma multiforme (GBM) and other cancers that are difficult or impossible to treat with traditional methods. Its development of low-energy neutron beams will be practical for installation in typical hospital settings.

Hill joins from Accuray Incorporated, where he held a variety of executive level roles including Senior Vice President of R&D, Senior Vice President of Corporate Development, and Chief Product Officer. Over his tenure he led efforts in product development, innovation, mergers, acquisitions, partnerships, and intellectual property development.

Hill was previously Vice President of Engineering at North American Scientific and held various research and development leadership roles at NOMOS Corporation, where he was an early innovator in the field of radiation therapy focusing on Intensity Modulated Radiation Therapy (IMRT), Image Guided Radiation Therapy (IGRT), tomotherapy, and Monte Carlo dose calculation.

“I joined TAE Life Sciences because I believe its unique approach to cancer treatment will have a significant impact on the lives of individuals battling the most lethal cancers,“ said Hill. “I am honored to be joining a talented team working hard to give hope to patients and families who need new therapeutic solutions.”

For more information about TAE Life Sciences, Alphabeam, and the company’s proprietary boronated BNCT drugs, please visit taelifesciences.com.

About TAE Life Sciences
TAE Life Sciences is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TAE Life Sciences is the only company developing the next-generation targeted boron drugs and low-energy accelerator-based neutron system optimized for an in-hospital BNCT program that delivers cancer-killing radiation with cellular-level precision to treat patients with aggressive and refractory cancers. TAE Life Sciences’ Alphabeam neutron system and targeted boron drugs are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at taelifesciences.com.